Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Bioventix ( (GB:BVXP) ) has provided an announcement.
Bioventix reported a 1% increase in revenue to £6.73 million for the six months ending December 2024, though profit before tax fell by 4% due to increased R&D spending. Despite steady sales in core antibodies, including vitamin D and troponin, the company is optimistic about future growth driven by increased sales of Tau antibodies for Alzheimer’s disease testing and ongoing research in industrial pollution and water quality projects. The interim dividend rose by 3% to 70p per share, reflecting the company’s commitment to shareholder returns. Bioventix anticipates a return to growth in 2026 as new applications for their antibodies gain traction, particularly in neurological blood testing and industrial applications.
More about Bioventix
Bioventix plc is a UK-based company that specializes in the development and commercial supply of high-affinity monoclonal antibodies, primarily for clinical diagnostics. These antibodies are particularly beneficial for detecting targets present at low concentrations and are used in automated immunoassays for blood testing. The company serves major multinational clinical diagnostics firms and offers products for diagnosing various conditions, including heart disease, cancer, fertility, thyroid function, and drug abuse.
YTD Price Performance: -13.39%
Average Trading Volume: 5,240
Technical Sentiment Signal: Buy
Current Market Cap: £143.5M
See more data about BVXP stock on TipRanks’ Stock Analysis page.